Quality-of-Life Advantages Seen With Tacrolimus After Kidney Transplant

NEW YORK (Reuters Health) Mar 25 – Among kidney transplant patients, quality of life after is better with tacrolimus than with cyclosporine-microemulsion immunosuppression, according to a report in the February issue of Clinical Transplantation.
Tacrolimus-based immunotherapy promises better graft survival after kidney transplant, the authors explain, but its use has been associated with increased rates of certain side effects that differ from those seen with cyclosporine treatment. Few studies have compared the disease-specific quality of life experienced with these two agents.

לכתבה המלאה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים